LivaNova (NSDQ:LIVN) said today that it is ending its Caisson Interventional transcatheter mitral valve replacement (TMVR) program and plans to restructure its heart valve business to improve profitability. The company’s heart valve business represented nearly $130 million in revenue during fiscal 2018 and saw its revenue numbers decline over the last five years, both with biological […]
caissoninterventional
LivaNova buys out Caisson Interventional for $72m
LivaNova (NSDQ:LIVN) yesterday said it put up $72 million to acquire the remaining stake in Caisson Interventional, which is developing a implantable device to replace the heart’s mitral valve. Maple Grove, Minn.-based Caisson’s transcatheter mitral valve replacement is designed to be delivered across the heaert’s septum via the femoral vein and can be repositioned or withdrawn before final […]
